Nouscom

Cell & Gene Therapy · Vaccines

Facts

as of Nov 19, 2026

Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Financials

Funding rounds, investors and revenue on record.

$135MTotal raised
Venture - Series UnknownLatest round
1Rounds and grants
Money by yearUSD, rounds and grants
2026$135M1 record
Largest rounds and grants
Sources: funding announcements, grant and company registers

Money

Nouscom has $135M paid in by investors, lenders and donors.

$135MPaid in
StagePaidSignedAnnouncedSourceFiledAnnouncedPress
Money in
Equity raised
Oct 2026 · Venture round
$135MPaid
Taxes
No public tax figures for this company or its entities.
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".

Milestones

Each milestone is dated by its source: registers, filings, the press

Newsroom

top 6%Web presenceof 133.2M domains by links, Common Crawl
Oct 192026
News · Tech Funding News
Nouscom's co-founder and original chief executive, Riccardo Cortese, died in 2017, the year after Marina Udier joined the…
Oct 192026
News · EU-Startups
Basel-based Nouscom, a clinical-stage, cancer interception focused BioTech developing next-generation immunotherapies, today announced the closing of an oversubscribed €120 milli…
Sources: the outlets named on each headline, each story once